Evidence map›Paper›PMID 42688649›Full record

ArticleTherapeutic advances in drug safety2026

Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature.

Lucie Regaldo-Saint Blancard, Simon Pernot, Marianne Fonck, Lola Jade Palmieri

Abstract readCase Reports
In one paragraph

Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lucie Regaldo-Saint BlancardMedical Oncology, Bergonié Institute, Bordeaux, Nouvelle-Aquitaine 33000, France.ORCID https://orcid.org/0009-0005-0400-8127
Simon PernotMedical Oncology, Bergonié Institute, Bordeaux, Nouvelle-Aquitaine, France.
Marianne FonckMedical Oncology, Bergonié Institute, Bordeaux, Nouvelle-Aquitaine, France.
Lola Jade PalmieriMedical Oncology, Bergonié Institute, Bordeaux, Nouvelle-Aquitaine, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin commonly induces acute, transient peripheral neurotoxicity, most often presenting as cold-induced paresthesia. Ocular adverse events are rare and poorly understood. This case describes a rare, reproducible transient monocular visual field loss associated with oxaliplatin exposure. We report a patient treated with FOLFOX (5-FU + oxaliplatin) for metastatic rectal cancer who developed recurrent transient visual symptoms temporally associated with oxaliplatin infusion. Biological, neurological, and ophthalmological evaluations were performed. The patient experienced recurrent, transient left monocular vertical hemifield loss during oxaliplatin administration. Extensive neurological and ophthalmological investigations were unremarkable. Symptoms were fully reversible and reproducible across treatment cycles, occurring exclusively after oxaliplatin exposure. This case adds to the limited literature on oxaliplatin-associated ocular neurotoxicity and emphasizes that transient visual symptoms may represent a reversible form of acute neurotoxicity. Recognizing this entity is important to avoid premature discontinuation of an effective chemotherapy regimen.

Indexed as

case reportneurotoxicityocular toxicityoxaliplatinside effects

Identifiers

PMID42688649
PMCPMC13535021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.